Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Laekna gets rights to Novartis cancer candidates

Laekna Therapeutics Shanghai Co. Ltd. (Shanghai, China) acquired exclusive, worldwide rights to develop and commercialize two clinical stage

Read the full 183 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE